1123827-71-3Relevant articles and documents
Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes
Guo, Liangqin,Parker, Dann L.,Zang, Yi,Sweis, Ramzi F.,Liu, Weiguo,Sherer, Edward C.,Buist, Nicole,Terebetski, Jenna,Kelly, Terri,Bugianesi, Randal,Priest, Birgit T.,Dingley, Karen H.,Li, Xiaofang,Mitelman, Stan,Salituro, Gino,Trujillo, Maria E.,Pachanski, Michele,Kirkland, Melissa,Powles, Mary Ann,Eiermann, George J.,Feng, Yue,Shang, Jin,Howard, Andrew D.,Ujjainwalla, Feroze,Sinz, Christopher J.,Debenham, John S.,Edmondson, Scott D.,Nargund, Ravi P.,Hagmann, William K.,Li, Derun
, p. 1107 - 1111 (2016/12/16)
GPR142 has been identified as a potential glucose-stimulated insulin secretion (GSIS) target for the treatment of type 2 diabetes mellitus (T2DM). A class of triazole GPR142 agonists was discovered through a high throughput screen. The lead compound 4 suffered from poor metabolic stability and poor solubility. Lead optimization strategies to improve potency, efficacy, metabolic stability, and solubility are described. This optimization led to compound 20e, which showed significant reduction of glucose excursion in wild-type but not in GPR142 deficient mice in an oral glucose tolerance test (oGTT) study. These studies provide strong evidence that reduction of glucose excursion through treatment with 20e is GPR142-mediated, and GPR142 agonists could be used as a potential treatment for type 2 diabetes.
Highly functional group tolerance in copper-catalyzed N-arylation of nitrogen-containing heterocycles under mild conditions
Zhu, Liangbo,Li, Gaocan,Luo, Liang,Guo, Peng,Lan, Jingbo,You, Jingsong
supporting information; experimental part, p. 2200 - 2202 (2009/07/01)
A copper-catalyzed process has been developed for the N-arylation reaction under very mild conditions in the absence of additional ligand. This protocol could not only tolerate an array of thermally sensitive functional groups, but also achieve high chemoselectivity.
